Lucigen, RCT Partner on Protein Expression System Lacking Endotoxin | GenomeWeb

NEW YORK (GenomeWeb News) – Lucigen and Research Corporation Technologies on Wednesday announced a commercialization and distribution partnership for the first Escherichia coli-based recombinant system without endotoxin.

The CleanColi Expression System is for protein expression and contains a genetically modified lipopolysaccharide that does not create an endotoxic response in human cells. Because of this, researchers will be able to increase their productivity since they will no longer need to remove unwanted endoxin, Lucigen and RCT said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.